All In Biotech

Drug Trial Radar · NCT06732180

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation

Last checked: Nov 20, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 21, 2025

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Gain Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: * What medical problems do participants have when taking GT-02287? * How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? * Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease? Participants will: * visit the clinic to assess if they qualify for the study (30-day Screening Period) * if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period) * visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period. * visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).

Conditions

  • Parkinson Disease

Interventions

  • GT-02287Drug

    Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)Time frame: From first dose to Day 105
  2. Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From first dose to Day 105

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Southern Neurology

    Kogarah, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • CMAX

    Adelaide, South Australia, Australia · Recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.